DSIP — Cellaire Labs

01 / Dosing schedule

Cited dosing

DSIP's human dosing record is small, old and consistent: 25 nmol/kg body weight, given intravenously, in sleep-laboratory studies from the 1980s and early 1990s. There is no modern trial, no approved product and no published subcutaneous protocol.

DSIP human sleep studies — 25 nmol/kg IV

Phase	Dose & frequency
Dose (all cited studies)	25 nmol/kg body weight
Route	slow intravenous infusion / intravenous injection
Healthy-volunteer study timing	given in the morning; sleep measured after a 130-min interval (6 volunteers)
Chronic insomnia study timing	in the afternoon before the 3rd, 4th and 5th laboratory nights (16 patients, double-blind)
Insomnia review	single injections of 25 nmol/kg before sleep; repeated administrations normalised sleep structure after four administrations
Higher doses	n.a. — a case of insomnia in organic brain disease is said to have responded to 'higher doses' with no amount given
Subcutaneous / intranasal dose	n.a. — not published in the sources fetched

Source · Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. ↗

Source indication · Human sleep behaviour in normal volunteers, and short-term treatment of chronic insomnia (sleep-laboratory studies)

Injection frequency: Single dose per occasion. Regimens used were one dose before sleep, one dose in the morning, or one dose on each of three consecutive afternoons.
Injection sites: n.a. — the studies report intravenous administration and do not name an infusion or injection site. No subcutaneous site appears anywhere in the human record.

02 / Reconstitution

Reconstitution reference

The 1980s-90s studies do not publish a reconstitution procedure or vial strength; the comparator in the insomnia trial was a glucose solution placebo. Note that dosing was weight-based in nmol/kg, so it cannot be converted to a flat microgram dose without the peptide's molar mass and the subject's weight.

Vialn.a. — not published

BAC watern.a.

Concentrationn.a.

Example dose25 nmol/kg body weight

On a U‑100 syringenmol/kg, intravenous — not a flat mcg dose

Open the reconstitution calculator →

03 / Overview

Protocol overview

DSIP is a nonapeptide isolated from rabbit cerebral venous blood in the 1970s and studied briefly in European sleep laboratories. It never reached a modern controlled trial programme, and no regulator has ever reviewed it.

Every human dose that can be cited is the same: 25 nmol/kg body weight intravenously. Schneider-Helmert and colleagues gave it as slow IV infusions in the morning to six normal volunteers and measured sleep after a 130-minute interval.

Bes and colleagues ran a double-blind matched-pairs study in 16 chronic insomniac patients who slept five consecutive nights in the laboratory; half received 25 nmol/kg IV DSIP and half a glucose placebo in the afternoon before the third, fourth and fifth nights.

A review of DSIP in insomnia adds that single injections of 25 nmol/kg were given before sleep, that repeated administration showed a build-up with sleep structure normalising after four administrations, and that two doses daily did not have the same effect. It mentions a case responding to 'higher doses' without stating them, so that cell is n.a. This record is flagged 'limited': the trials are real but tiny, decades old and IV-only.

04 / References